Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Gwenn Hansen Sells 3,957 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,957 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $26.28, for a total transaction of $103,989.96. Following the sale, the insider directly owned 123,452 shares in the company, valued at approximately $3,244,318.56. This trade represents a 3.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Monday, November 2nd, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $26.80, for a total value of $38,913.60.
• On Thursday, October 15th, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $36,300.00.
• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96.

Nurix Therapeutics Stock Down 4.1%

Shares of NASDAQ:NRIX traded down $1.10 on Monday, reaching $25.70. The company had a trading volume of 2,348,532 shares, compared to its average volume of 2,495,734. The stock has a market capitalization of $2.81 billion, a P/E ratio of 11.80 and a beta of 1.82. The stock has a 50-day moving average price of $24.98 and a 200 day moving average price of $20.20. Nurix Therapeutics, Inc. has a twelve month low of $11.67 and a twelve month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Monday, October 12th. The company reported $4.73 EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The company had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Nurix Therapeutics in the 2nd quarter valued at about $212,769,000. Perceptive Advisors LLC grew its position in Nurix Therapeutics by 4.4% during the first quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after buying an additional 155,000 shares in the last quarter. Trails Edge Capital Partners LP bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth $38,166,318. Bank of America Corp DE bought a new position in Nurix Therapeutics during the second quarter valued at approximately $20,429,000. Finally, Handelsbanken Fonder AB boosted its holdings in Nurix Therapeutics by 15.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 633,000 shares of the company’s stock valued at $15,357,000 after acquiring an additional 86,000 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Robert W. Baird boosted their price objective on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, October 15th. Morgan Stanley upped their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Oppenheimer upped their price target on shares of Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Finally, HC Wainwright upped their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, October 16th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.79.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.